ObsEva (NASDAQ:OBSV) versus Galecto (NASDAQ:GLTO) Head-To-Head Contrast

Galecto (NASDAQ:GLTO) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Galecto and ObsEva, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galecto	0	0	1	0	3.00
ObsEva	0	0	0	0	0.00

Galecto currently has a consensus price target of $10.00, indicating a potential upside of 81.82%. Given Galecto’s stronger consensus rating and higher probable upside, research analysts plainly believe Galecto is more favorable than ObsEva.

Profitability

This table compares Galecto and ObsEva’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Galecto	N/A	-76.96%	-66.59%
ObsEva	N/A	-416.36%	-92.01%

Risk & Volatility

Galecto has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

Insider & Institutional Ownership

14.2% of Galecto shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 11.9% of Galecto shares are held by insiders. Comparatively, 14.4% of ObsEva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Galecto and ObsEva”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galecto	N/A	N/A	-$38.35 million	($19.14)	-0.29
ObsEva	$20.11 million	0.00	-$58.38 million	($0.92)	N/A

Galecto has higher earnings, but lower revenue than ObsEva. Galecto is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Summary

Galecto beats ObsEva on 7 of the 12 factors compared between the two stocks.

About Galecto

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

About ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.